Editas Medicine (EDIT) Expected to Announce Quarterly Earnings on Wednesday

Editas Medicine (NASDAQ:EDIT) is expected to be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect Editas Medicine to post earnings of ($0.43) per share and revenue of $37.17 million for the quarter.

Editas Medicine Trading Up 4.7 %

Shares of Editas Medicine stock opened at $2.01 on Tuesday. The business’s fifty day simple moving average is $1.38 and its 200 day simple moving average is $2.54. The firm has a market capitalization of $165.92 million, a P/E ratio of -0.79 and a beta of 1.94. Editas Medicine has a 12 month low of $1.12 and a 12 month high of $11.58.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on EDIT. Stifel Nicolaus lowered Editas Medicine from a “buy” rating to a “hold” rating and dropped their price target for the stock from $11.00 to $3.00 in a report on Friday, December 13th. Chardan Capital reiterated a “neutral” rating on shares of Editas Medicine in a report on Friday, December 13th. Raymond James lowered Editas Medicine from an “outperform” rating to a “market perform” rating in a report on Monday, November 4th. Robert W. Baird dropped their price target on Editas Medicine from $10.00 to $8.00 and set an “outperform” rating on the stock in a report on Friday, December 13th. Finally, JPMorgan Chase & Co. lowered Editas Medicine from a “neutral” rating to an “underweight” rating in a research note on Monday, December 16th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $7.00.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.